Urolina A łagodzi zaburzenia zachowania i połączeń nerwowych związane z epilepsją
Urolithin A mitigates behavioural and synaptic deficits associated with epilepsy
W skrócie
Naukowcy badali naturalną substancję zwaną uroliną A, która może pomóc w leczeniu epilepsji opornej na leki. W doświadczeniach na owadach i myszach stwierdzili, że urolina A zmniejsza ataki padaczkowe i naprawia uszkodzone połączenia między neuronami, działając poprzez białko o nazwie VDAC1. Odkrycie to otwiera nowe możliwości rozwoju leków, które zamiast tylko tłumić ataki, mogłyby faktycznie hamować postęp choroby.
Oryginalny abstract (angielski)
BACKGROUND: The persistence of drug-resistant epilepsy highlights the need for new therapies that target novel mechanisms while maintaining synaptic strength and minimizing side effects. Small molecules of natural origin with anti-epileptogenic potential can influence altered synaptic deficits and reducing seizure threshold, offering a strategy to restore cellular energy homeostasis and slow the progression of epilepsy and associated comorbidities. METHODS: We used a combination of approaches including behavioural assays, immunostaining and electrophysiological recordings to study the synaptic contributions to reduced seizure-threshold in both Drosophila and mouse models of epilepsy. In addition, we used affinity-purification with synthesized beads specific for our small molecule to identify its cellular partners. RESULTS: We found that administration of Urolithin-A (UA), a small molecule of natural origin, mitigated behavioural and synaptic dysfunctions under chemically and genetically induced epileptic conditions in Drosophila. Additionally, chronic treatment with UA attenuated the altered single-cell and network synaptic transmission in PTZ-induced chronic kindling of mice. However, UA exerted no seizure-suppressive effects in in vitro epileptic conditions, suggesting the absence of acute anti-epileptic effects. In addition, we identified the direct interactor of UA as the complex of tubulin dimer and VDAC1. Molecular docking analyses also predicted that urolithin A interacts with VDAC1. Consistent with the neuroprotective role of VDAC1 downregulation reported in previous studies, neuron-specific knockdown of VDAC1 in Drosophila phenocopied the effects of UA. CONCLUSIONS: Collectively, our data show that UA exerts disease-modifying anti-epileptic effects in both Drosophila and mouse models with VDAC1 identified as a critical functional mediator; however, direct functional modulation of VDAC1 and associated partners by UA will require further experimental validation. These findings provide the blueprint for future drug discovery targeting VDAC1-dependent pathways.